Flomax Related Published Studies
Well-designed clinical trials related to Flomax (Tamsulosin)
Tamsulosin for ureteral stones in the emergency department: a randomized, controlled trial. [2009.09]
[Combination of tolterodine and tamsulosin for benign prostatic hyperplasia] [2009.07]
A second cycle of tamsulosin in patients with distal ureteric stones: a prospective randomized trial. [2009.06]
Comparison of tamsulosin with extracorporeal shock wave lithotripsy in treating distal ureteral stones. [2009.04.05]
[One-week effects of Tamsulosin on benign prostatic hyperplasia assessed with a daily symptom score] [2009.04]
Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. [2009.04]
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. [2009.04]
Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. [2009]
Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. [2008.12]
Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. [2008.12]
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. [2008.11]
Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. [2008.11]
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. [2008.11]
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. [2008.09]
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. [2008.09]
Effectiveness of low-dose and standard-dose tamsulosin in the treatment of distal ureteric stones: a randomized controlled study. [2008.05]
Tamsulosin treatment of chronic non-bacterial prostatitis. [2008.03]
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. [2008.02]
Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi? [2007.06]
Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. [2007.04]
A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. [2007]
The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. [2006.12]
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. [2006.11.15]
Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. [2006.10]
Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. [2006.04]
Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). [2006.03]
Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. [2006.01]
Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. [2006]
Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. [2005.11]
Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. [2005.10]
A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. [2005.09]
Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. [2005.09]
Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. [2005.07]
Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. [2005.07]
Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. [2005.07]
Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. [2005.05.01]
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. [2005.05]
Tamsulosin in the treatment of LUTS/BPH: an Italian multicentre trial. [2005.03]
The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. [2005.03]
Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. [2005.02]
Intermittent tamsulosin therapy in men with lower urinary tract symptoms. [2005.01]
Does tamsulosin enhance lower ureteral stone clearance with or without shock wave lithotripsy? [2004.12]
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. [2004.11]
Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. [2004.11]
Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. [2004.10.19]
Nifedipine versus tamsulosin for the management of lower ureteral stones. [2004.08]
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis] [2004.06]
Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. [2004.06]
Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. [2004.04]
Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. [2004.01]
Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. [2003.12]
Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. [2003.11]
Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. [2003.10]
A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. [2003.03]
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. [2003.01]
A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. [2003]
Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. [2002.11]
[Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial] [2002.06]
[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study] [2002.06]
[Clinical evaluation of the effect of tamsulosin hydrochloride and cernitin pollen extract on urinary disturbance associated with benign prostatic hyperplasia in a multicentered study] [2002.05]
Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. [2002.05]
Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. [2002.01]
Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker--Tamsulosin. [2002]
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy] [2001.01]
A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. [2000.11]
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. [2000.06]
Antagonistic activity of tamsulosin against human vascular alpha1-adrenergic receptors. [2000.04]
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. [2000.04]
Terazosine and tamsulosin in non bacterial prostatitis: a randomized placebo-controlled study. [1999.12]
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. [1999.12]
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. [1999.10]
A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors. [1999.07]
Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin. [1999.01]
A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. [1998.11]
Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. [1998.06]
Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. [1998.01]
[Treatment of benign prostatic hyperplasia with tamsulosin] [1998]
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. [1998]
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. [1998]
Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. [1997.10]
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. [1997.10]
A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). [1997.10]
Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. [1997.07]
Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group. [1996.10]
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. [1996]
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. [1996]
Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. [1995.09]
Well-designed clinical trials possibly related to Flomax (Tamsulosin)
Safety and Tolerability of Solifenacin Add-on Therapy to alpha-Blocker Treated Men With Residual Urgency and Frequency. [2009.10.16]
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. [2009.10.07]
Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. [2009.06]
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. [2009.04]
Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones. [2009]
[Economic evaluation of medical treatment of benign prostatic hyperplasia (BPH) in the specialised care setting in Spain. Application to the cost-effectiveness of two drugs frequently used in its treatment] [2008.10]
Role of alpha1-blockers in chronic prostatitis syndromes. [2008.03]
Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. [2008.03]
A systematic review of medical therapy to facilitate passage of ureteral calculi. [2007.11]
[Comparison of different drugs on the treatment of benign prostate hyperplasia] [2007.07.15]
The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial. [2006.12]
Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. [2006.10.31]
The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. [2005.06]
Brachytherapy-related dysuria. [2005.03]
|
